

Felix Vajdos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6346325/publications.pdf>

Version: 2024-02-01

25
papers

7,091
citations

331670

21
h-index

580821

25
g-index

26
all docs

26
docs citations

26
times ranked

9147
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery of Potent and Selective Periphery-Restricted Quinazoline Inhibitors of the Cyclic Nucleotide Phosphodiesterase PDE1. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 4635-4640.	6.4	19
2	Identification of Cyanamide-Based Janus Kinase 3 (JAK3) Covalent Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10665-10699.	6.4	55
3	Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of ((S)-2,2-Difluorocyclopropyl)((R,S)-3-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[5.1.0]octan-8-yl)propan-1-amine (PF-06700841). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 8597-8612.	6.4	26
4	Discovery of 3-Cyano-N-(3-(1-isobutryl)piperidin-4-yl)-1-methyl-4-(trifluoromethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)benzamide: A Potent, Selective, and Orally Bioavailable Retinoic Acid Receptor-Related Orphan Receptor C2 Inverse Agonist. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 10415-10439.	6.4	26
5	Design of a Janus Kinase 3 (JAK3) Specific Inhibitor 1-((S,S)-5-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one (PF-06651600) Allowing for the Interrogation of JAK3 Signaling in Humans. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1971-1993.	6.4	111
6	Aminomethyl-Derived Beta Secretase (BACE1) Inhibitors: Engaging Gly230 without an Anilide Functionality. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 386-402.	6.4	33
7	Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. <i>ACS Chemical Biology</i> , 2016, 11, 3442-3451.	3.4	127
8	Discovery of spirocyclic-diamine inhibitors of mammalian acetyl CoA-carboxylase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 5352-5356.	2.2	13
9	Discovery of a Series of Efficient, Centrally Efficacious BACE1 Inhibitors through Structure-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2678-2702.	6.4	42
10	Decreasing the Rate of Metabolic Ketone Reduction in the Discovery of a Clinical Acetyl-CoA Carboxylase Inhibitor for the Treatment of Diabetes. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 10512-10526.	6.4	74
11	Small-molecule phosphodiesterase probes: discovery of potent and selective CNS-penetrable quinazoline inhibitors of PDE1. <i>MedChemComm</i> , 2014, 5, 1290-1296.	3.4	31
12	Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3059-3063.	2.2	10
13	Spirocyclic Sulfamides as β -Secretase 1 (BACE-1) Inhibitors for the Treatment of Alzheimer's Disease: Utilization of Structure Based Drug Design, WaterMap, and CNS Penetration Studies To Identify Centrally Efficacious Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9224-9239.	6.4	60
14	Discovery and Optimization of a Novel Spiropyrrolidine Inhibitor of β -Secretase (BACE1) through Fragment-Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 9069-9088.	6.4	54
15	Structure-guided Inhibitor Design for Human Acetyl-coenzyme A Carboxylase by Interspecies Active Site Conversion. <i>Journal of Biological Chemistry</i> , 2011, 286, 41510-41519.	3.4	5
16	Discovery of small molecule isozyme non-specific inhibitors of mammalian acetyl-CoA carboxylase 1 and 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 2383-2388.	2.2	55
17	Antitumor Activity and Pharmacology of a Selective Focal Adhesion Kinase Inhibitor, PF-562,271. <i>Cancer Research</i> , 2008, 68, 1935-1944.	0.9	348
18	The 2.0 Å... crystal structure of the ERK ligand-binding domain complexed with lasofoxfene. <i>Protein Science</i> , 2007, 16, 897-905.	7.6	54

#	ARTICLE	IF	CITATIONS
19	Suppressor of Fused Regulates Gli Activity through a Dual Binding Mechanism. <i>Molecular and Cellular Biology</i> , 2004, 24, 8627-8641.	2.3	117
20	Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. <i>Cancer Cell</i> , 2004, 5, 317-328.	16.8	977
21	Structural insights into the catalytic mechanism of cyclophilin A. <i>Nature Structural and Molecular Biology</i> , 2003, 10, 475-481.	8.2	141
22	Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis. <i>Journal of Molecular Biology</i> , 2002, 320, 415-428.	4.2	111
23	Crystal structure of cyclophilin A complexed with a binding site peptide from the HIV-1 capsid protein. <i>Protein Science</i> , 1997, 6, 2297-2307.	7.6	84
24	Crystal Structure of Human Cyclophilin A Bound to the Amino-Terminal Domain of HIV-1 Capsid. <i>Cell</i> , 1996, 87, 1285-1294.	28.9	686
25	How to measure and predict the molar absorption coefficient of a protein. <i>Protein Science</i> , 1995, 4, 2411-2423.	7.6	3,742